Skip to main content
GIPResearch.com · Patent and Technology Research

THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION Received Patent For NEW HUMAN ROTAVIRUS STRAINS AND VACCINES

The United States Centers for Disease Control & Prevention operates as a department within the United States Department of Health and Human Services.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for THE GOVERNMENT OF THE UNITED STATES OF AMERICA  AS REPRESENTED BY THE SECRETARY  DEPARTMENT OF HEALT
Research and original publication material

THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION Received Patent For NEW HUMAN ROTAVIRUS STRAINS AND VACCINES — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

The United States Centers for Disease Control & Prevention operates as a department within the United States Department of Health and Human Services. The Agency strives to protect the health and safety of the public through dissemination of information to improve decisions made regarding health. CDC develops and implements disease prevention regulations and health education programs. In India, the Pharmaceutical business of The United States of America is focused on Recombinant rift valley fever (RVF) viruses and methods of use, Recombinant rift valley fever (RVF) viruses and methods of use, Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs. The Government of the United States of America filed patent application numbered 9731/DELNP/2011 that is titled as NEW HUMAN ROTAVIRUS STRAINS AND VACCINES. This patent application has been granted as Patent Number 316869. The invention covers Biotechnology compounds.  A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the Claims 1-18 relates to a vaccine composition comprising a carrier admixed with a rotavirus strain of CDC-9 or CDC-66, Which is already given in prior art. The Applicant submits that original claims 4, 11, 13-14 and 17-18 are deleted.  Also, As a response to said objection, the applicant submitted that the scientific comparison and arguments are presented to differentiate. Also, the prior art gives insufficient information to bring similarity and the new product is novel. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to THE GOVERNMENT OF THE UNITED STATES OF

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-09-10. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights